Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

maurizio58 Apr. 1 at 5:05 PM

$PHIO we are on the right track

0 · Reply

DosGatos Mar. 31 at 6:46 PM

$PHIO

0 · Reply

DERDER Mar. 31 at 5:43 PM

$PHIO

0 · Reply

KuruHabesha Mar. 31 at 1:43 PM

$PHIO Back in!

0 · Reply

Stock_Catcher Mar. 31 at 1:04 PM

$PHIO Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

0 · Reply

kaefer Mar. 31 at 12:05 PM

$PHIO Let’s bullish harami and bear trap‼️😈

0 · Reply

DosGatos Mar. 31 at 10:48 AM

$PHIO

1 · Reply

DERDER Mar. 30 at 6:34 PM

$PHIO you’re the scam!

0 · Reply

DERDER Mar. 30 at 6:33 PM

$PHIO

0 · Reply

DosGatos Mar. 30 at 6:28 PM

$PHIO

0 · Reply

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

Mar 23, 2026, 7:00 AM EDT - 10 days ago

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

Mar 16, 2026, 11:30 AM EDT - 16 days ago

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Mar 10, 2026, 8:35 AM EDT - 23 days ago

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

Mar 10, 2026, 7:00 AM EDT - 23 days ago

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Mar 5, 2026, 4:05 PM EST - 27 days ago

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Mar 5, 2026, 7:00 AM EST - 4 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Feb 12, 2026, 8:43 AM EST - 7 weeks ago

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

Feb 10, 2026, 11:12 AM EST - 7 weeks ago

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Feb 10, 2026, 7:00 AM EST - 7 weeks ago

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Jan 26, 2026, 8:15 AM EST - 2 months ago

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Jan 20, 2026, 9:30 AM EST - 2 months ago

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 15, 2026, 8:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Dec 23, 2025, 8:45 AM EST - 3 months ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025, 11:30 AM EST - 4 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 17, 2025, 8:45 AM EST - 4 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 4 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 10:30 AM EST - 5 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 5 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 5 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 5 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Sep 18, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 8 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 8 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 8 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 11 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 11 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 11 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 1 year ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

maurizio58 Apr. 1 at 5:05 PM

$PHIO we are on the right track

0 · Reply

DosGatos Mar. 31 at 6:46 PM

$PHIO

0 · Reply

DERDER Mar. 31 at 5:43 PM

$PHIO

0 · Reply

KuruHabesha Mar. 31 at 1:43 PM

$PHIO Back in!

0 · Reply

Stock_Catcher Mar. 31 at 1:04 PM

$PHIO Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

0 · Reply

kaefer Mar. 31 at 12:05 PM

$PHIO Let’s bullish harami and bear trap‼️😈

0 · Reply

DosGatos Mar. 31 at 10:48 AM

$PHIO

1 · Reply

DERDER Mar. 30 at 6:34 PM

$PHIO you’re the scam!

0 · Reply

DERDER Mar. 30 at 6:33 PM

$PHIO

0 · Reply

DosGatos Mar. 30 at 6:28 PM

$PHIO

0 · Reply

vinkush1 Mar. 30 at 4:12 PM

$PHIO no movement 😐 but good news tho!

0 · Reply

PitaPierogi Mar. 30 at 11:53 AM

$PHIO BIG TIME NEWS

0 · Reply

MrBruceWayne Mar. 30 at 11:36 AM

🚨💎 BUY ALERT $PHIO

0 · Reply

DARKP00L Mar. 30 at 11:29 AM

$PHIO 07:22 on Mar. 30 2026 Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply #tradeideas

0 · Reply

MambaMentality7 Mar. 30 at 11:16 AM

$PHIO today you're going to see so good spikes maybe 2.00 high but it's not the run. The best is yet to come. Don't get ahead of yourself. It will give most of the gains back by the end of the day. Most that jumped in will get trapped and panic sell to smart money who purchase at a discount all who panic. There was great news over the weekend and better news to come. The smart play is to wait for the panic and buy more at a discount, bring down your average. Be patient.....

0 · Reply

topstockalerts Mar. 30 at 11:03 AM

$PHIO known for big spikes

0 · Reply

Deblitorator Mar. 30 at 11:02 AM

$ASTC I will keep adding more I kow this is going for new highs soon $ANNA $PHIO WW too both starting to trend

0 · Reply

newsfile_corp Mar. 30 at 11:00 AM

https://nfne.ws/290314 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

kaefer Mar. 29 at 7:39 PM

$PHIO Saturday‘s presentation was positive. Glad to hear! https://phiopharma.com/events-presentations/?utm_source=copilot.com

0 · Reply

Lreyn84702 Mar. 27 at 7:12 PM

$PHIO I see negative stock split down the road and more dilution. That is how these guys operate. Been there done that.

0 · Reply

PitaPierogi Mar. 27 at 1:44 PM

$PHIO 4.

0 · Reply

MambaMentality7 Mar. 27 at 1:36 PM

$PHIO YOU SEE THEM PULLING IN STOCK DOWN IT'S NOW AT 1.27 AND WENT DOWN TO 1.24 DON'T PANIC! YOU YOU WILL SEE A BIT OF PANIC SELLING WHICH IS WHAT THEY WANT ALL THOSE SHARES WILL BE BOUGHT UP BY SMART MONEY. THIS IS THE PLAY BE PATIENT DON'T SELL HOLD IF YOU CAN BUY MORE. THEY TRY TO PULL IT DOWN BUT THEY WILL ONLY LET IT GO SO FAR. THIS IS POSITIONING AND ACCUMULATION ONLY. THE STOCK WILL NOT STAY DOWN.

0 · Reply

Market Cap	14.17M
Revenue (ttm)	0.00
Net Income (ttm)	-8.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	475,500
Avg Vol	4,583,550
Day's Range	N/A - N/A
Shares Out	11.62M
Stochastic %K	72%
Beta	0.90
Analysts	Sell
Price Target	$14.00